NeuroPace develops implantable neurostimulation systems for treating drug-resistant focal epilepsy. The company's primary product is the RNS System, a brain-responsive device that delivers personalized, real-time electrical stimulation directly at the seizure source. The system comprises an implantable neurostimulator, cortical strip and depth leads for brain signal detection, and a patient remote monitor that allows wireless communication between the device and healthcare providers. The RNS System is designed for patients whose seizures cannot be adequately controlled through pharmaceutical intervention.
Revenue is generated through hospital facility sales for both initial implant procedures and device replacement procedures. The company also provides supporting software infrastructure, including physician tablets, patient data management systems, and the nSight Platform, which enables ongoing patient monitoring and facilitates patient support workflows. The nSight Platform streamlines clinical management and data collection for treating physicians.
Based in Mountain View, California, NeuroPace operates with approximately 209 full-time employees and maintains a primary focus on the U.S. market. The company was incorporated in 1997 and is listed on the Nasdaq exchange. With a current market capitalization of $0.5 billion, NeuroPace operates at a smaller scale within the medical device sector, reflecting the specialized nature of its therapeutic focus and the limited patient population for focal epilepsy treatment.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.93 | $-0.93 | +26.8% | |
| 2023 | $-1.27 | $-1.27 | +33.5% | |
| 2022 | $-1.91 | $-1.91 | +12.0% | |
| 2021 | $-2.17 | $-2.17 | — |